We are live on ! Find out more
BLRX

BioLineRX
BLRX

26 hedge funds and large institutions have $7.28M invested in BioLineRX in 2016 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 4

13% more funds holding

Funds holding: 23 → 26 (+3)

0% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 5

46% less capital invested

Capital invested by funds: $13.6M → $7.28M (-$6.32M)

Holders
26
Holders Change
+3
Holders Change %
+13.04%
% of All Funds
0.69%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
5
Reduced
5
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$162K
2
VKH
Virtu KCG Holdings
New York
+$142K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$40.8K
4
TSS
Two Sigma Securities
New York
+$21.4K
5
Bank of America
Bank of America
North Carolina
+$17K

Top Sellers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
-$4.55M
2
Millennium Management
Millennium Management
New York
-$105K
3
SM
Senvest Management
New York
-$62.8K
4
Morgan Stanley
Morgan Stanley
New York
-$25.8K
5
AL
Airain Ltd
Guernsey
-$19K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Senvest Management
New York
$3.62M -$62.8K -100 -2%
O
2
OrbiMed
New York
$1.06M – – –
Alyeska Investment Group
3
Alyeska Investment Group
Illinois
$612K +$162K +258 +35%
Millennium Management
4
Millennium Management
New York
$510K -$105K -167 -17%
Morgan Stanley
5
Morgan Stanley
New York
$441K -$25.8K -41 -5%
OM
6
Opaleye Management
Massachusetts
$255K – – –
Deutsche Bank
7
Deutsche Bank
Germany
$248K – – –
VKH
8
Virtu KCG Holdings
New York
$138K +$142K +226 New
MC
9
Menta Capital
California
$101K +$10.7K +17 +11%
BCA
10
Benchmark Capital Advisors
New York
$48K – – –
LTFS
11
Ladenburg Thalmann Financial Services
Florida
$41K +$5.65K +9 +16%
NFG
12
Next Financial Group
Texas
$40K +$1.89K +3 +5%
Susquehanna International Group
13
Susquehanna International Group
Pennsylvania
$40K +$40.8K +65 New
Commonwealth Equity Services
14
Commonwealth Equity Services
Massachusetts
$23K – – –
TSS
15
Two Sigma Securities
New York
$21K +$21.4K +34 New
Bank of New York Mellon
16
Bank of New York Mellon
New York
$18K – – –
Bank of America
17
Bank of America
North Carolina
$17K +$17K +27 New
Creative Planning
18
Creative Planning
Kansas
$15K -$8.17K -13 -34%
PAG
19
Private Advisor Group
New Jersey
$15K +$15.7K +25 New
PNC Financial Services Group
20
PNC Financial Services Group
Pennsylvania
$10K – – –
Royal Bank of Canada
21
Royal Bank of Canada
Ontario, Canada
$4K +$1.26K +2 +40%
UBS Group
22
UBS Group
Switzerland
$2K -$6.91K -11 -79%
WCM
23
Wealthcare Capital Management
Virginia
$2K +$1.89K +3 New
KF
24
Krilogy Financial
Missouri
$1K – – –
Wells Fargo
25
Wells Fargo
California
$1K – – –
1
2

BLRX Hedge Fund Activity: Q1 2016 in Review

26 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q1 2016, worth a combined $7.28M — down 46% from $13.6M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new BLRX positions and 4 closed out — a net gain of 3 holders — while 5 added to existing stakes and 5 trimmed.

The largest buyer was Alyeska Investment Group, adding an estimated $162K. The largest seller was Broadfin Capital, exiting entirely with an estimated $4.55M sold.

  • 26 institutional investors held BioLineRX (BLRX) as of Q1 2016, up from 23 in Q4 2015.
  • Funds reported $7.28M of BioLineRX stock for Q1 2016, down 46% quarter-over-quarter.
  • 7 funds opened new BioLineRX positions in Q1 2016 and 4 closed out, a net change of +3 holders.
  • The largest BioLineRX buyer in Q1 2016 was Alyeska Investment Group, an estimated $162K added.
  • The largest BioLineRX seller in Q1 2016 was Broadfin Capital, an estimated $4.55M sold.

Based on aggregated 13F filings for Q1 2016.